Deals

BMS sees potential first-in-class therapy in deal for Agenus’ bispecific TIGIT-targeting mAb

BMS’s belief that Agenus has built a differentiated TIGIT-targeting bispecific molecule has resulted in a potentially transformative deal for the biotech, delivering $200 million up front for the preclinical program to fuel its further